This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.
Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
CMS does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
27/06/2012
CMS Bureau Francis Lefebvre has advised the shareholders of Finesco, the sole shareholder of Scomedica, a leading French healthcare contract sales organisation, for the contribution of their shares to Apricus Bio, an American pharmaceutical company listed on the NASDAQ market.
CMS Bureau Francis Lefebvre announced today that it advised the shareholders of Finesco-Scomedica, a leading French healthcare contract sales organisation, for the contribution of all of their outstanding shares to Apricus Biosciences Inc., an American pharmaceutical company listed on the NASDAQ market.
Under the terms of the share contribution agreement, Finesco shareholders will contribute to Apricus Bio 100% of the outstanding common stock of Finesco in exchange for newly issued shares of Apricus Bio common stock valued at €7 million (around $8.8 million). If Scomedica achieves certain revenue milestones during 2012, the Finesco shareholders could receive all of an additional issue of new shares worth up to €1.8 million (around $2.3 million) in the first quarter of 2013. Finesco and Scomedica will become wholly-owned subsidiaries of Apricus Bio.
Finesco/Scomedica advisors (France):
CMS Bureau Francis Lefebvre (Benoit Provost and Thomas Bortoli)
Finesco/Scomedica advisors (USA):
Kilpatrick Townsend & Stockton LLP (Richard Cicchillo and David Eaton)
Apricus Bio advisors (France):
Salans (Jean-Marc Grosperrin and Stéphane Jaffrain).
For more nformation, please contact:
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.